<DOC>
	<DOCNO>NCT00551928</DOCNO>
	<brief_summary>To compare efficacy combination lenalidomide low-dose melphalan versus high-dose melphalan newly diagnose , symptomatic MM patient .</brief_summary>
	<brief_title>Lenalidomide Melphalan Prednisone Versus High Dose Melphalan Newly Diagnosed Multiple Myeloma Patients</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Patient , investigator ( ) opinion , willing able comply protocol requirement . Patient give voluntary write informed consent performance studyrelated procedure part normal medical care , understand consent may withdraw patient time without prejudice future medical care . Patient 65 year old young time signing informed consent Female patient either postmenopausal surgically sterilize willing use acceptable double method birth control ( i.e. , hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide , abstinence ) duration study . Negative serum βhuman chorionic gonadotropin ( βHCG ) pregnancy test 24 hour prior begin therapy 4 week interval woman regular menstrual cycle every 2 week woman irregular menstrual cycle study treatment subject childbearing potential Male patient agree use acceptable method contraception ( i.e. , condom abstinence ) study drug therapy ( include dose interruption ) 4 week discontinuation lenalidomide therapy . Patient diagnose symptomatic multiple myeloma base standard criterion ( 9 ) , measurable disease , define follow : quantifiable serum monoclonal protein value ( generally , necessarily , great 1 g/dL IgG MProtein great 0.5 g/dL IgA MProtein ) , applicable , urine lightchain excretion &gt; 200 mg/24 hour ; measurable plasmacytoma &gt; 2 cm determine clinical examination applicable radiograph ( i.e . MRI , CTScan ) ; bone marrow plasma cell &gt; 10 % . Patient Karnofsky performance status ≥ 60 % . Patient lifeexpectancy &gt; 6 month Patient active infectious hepatitis type B C , HIV negative test Patients must ejection fraction ECHO MUGA &gt; 50 % perform within 60 day prior registration Patients must adequate pulmonary function study &gt; 50 % predict mechanical aspect ( FEV1 , FVC , etc ) diffusion capacity ( DLCO ) &gt; 50 % predict . Patients unable complete pulmonary function test myelomarelated chest pain , must high resolution CT scan chest must also acceptable arterial blood gas define P02 great 70 . Patient follow laboratory value within 14 day Baseline ( day 1 Cycle 1 ) : Platelet count ≥ 75 x 109/L without transfusion support within 7 day test . Absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L without use growth factor . Corrected serum calcium ≤ 14 mg/dL ( 3.5 mmol/L ) . Aspartate transaminase ( AST ) : ≤ 2.5 x upper limit normal ( ULN ) . Alanine transaminase ( ALT ) : ≤ 2.5 x ULN . Total bilirubin : ≤ 1.5 x ULN . Calculated measured creatinine clearance : ≥ 30 mL/minute Patient baseline bone marrow sample available cytogenetics , process eventually centralize within country . Previous treatment antimyeloma therapy ( include radiotherapy , bisphosphonates , single short course steroid ; &lt; equivalent dexamethasone 40 mg/day 4 day ) . Any serious medical condition , include presence laboratory abnormality , place subject unacceptable risk participates study confounds experimental ability interpret data study . Pregnant lactate female . Prior history malignancy , multiple myeloma , unless subject free disease ≥ 3 year . Exceptions include follow : Basal cell carcinoma skin , Squamous cell carcinoma skin , Carcinoma situ cervix , Carcinoma situ breast , Incidental histologic find prostate cancer ( TNM stage T1a T1b ) Neuropathy ≥ grade 2 severity . Patients previously diagnose bear deep venous thrombosis arterial thromboembolic event within late 12 month , bear clear indication antiplatelet anticoagulant therapy bearing high risk bleed complication ineligible substudy protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>High dose Melphalan</keyword>
	<keyword>Mobilization</keyword>
	<keyword>CD34</keyword>
</DOC>